Molecular dissection of human oncostatin M-mediated signal transductions through site-directed mutagenesis

International Journal of Molecular Medicine

Volumn 23, Issue 2, 2009, Pages 161-172

  Liu, Haiyan ^a   Fenollar Ferrer, Cristina ^b   Cao, Aiqin ^a,c   Anselmi, Claudio ^b   Carloni, Paolo ^b   Liu, Jingwen ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b SISSA   (Italy)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Gene expression; Molecular modeling; Oncostatin M; Oncostatin M receptors; Signal transduction; Site directed mutagenesis

Indexed keywords

ALANINE; ASPARAGINE; ASPARTIC ACID; FIBRINOGEN; GLUTAMINE; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; STAT1 PROTEIN; STAT3 PROTEIN; THREONINE; OSM PROTEIN, HUMAN;

ARTICLE; BIOASSAY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; ANIMAL; CELL CULTURE; CELL STRAIN COS1; CERCOPITHECUS; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC TRANSFECTION; GENETICS; METABOLISM; MUTATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; ONCOSTATIN M; RECEPTORS, LDL; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 64749085611     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000113     Document Type: Article

References (36)

1. Liu J, Modrell B, Aruffo A, Marken JS, Taga T, Murakami M, Yasukawa K, Kishimoto T and Shoyab M: Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. J Biol Chem 267: 16763-16766, 1992.
2. Liu J, Modrell B, Aroffo A, Scharnowske S and Shoyab M: Interactions between Oncostatin M and the IL-6 signal transducer, gp130. Cytokine 6: 272-278, 1997.
3. Taga T and Kishimoto T: Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819, 1997.
4. Timmermann A, Pflanz S, Grotzinger J, Kuster A, Kurth I, Pitard V, Heinrich PC and Muller-Newen G: Different epitopes are required for gp130 activation by interleukin-6, oncostatin M, and leukemia inhibitory factor. FEBS Lett 468: 120-124, 2000.
5. Tanaka M and Miyajima A: Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149: 39-52, 2003.
6. Richard CD, Brown TJ, Shoyab M, Bauman H and Gauldie J: Recombinant oncostatin M stimulates the production of acute phase protein in HepG2 cells and rat primary hepatocytes in vitro. J Immunol 148: 1731-1736, 1992.
7. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokines signaling and its regulation Biochem J 374: 1-20, 2003.
8. Wang Y, Robledo O, Kinzie E, Blanchard F, Richards C, Miyajima A and Bauman H: Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem 275: 25273-25285, 2000.
9. Gearing DP and Bruce AG: Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol 4: 61-65, 1991.
10. Gearing DP, Comeau MR, Friend DJ, Gimpel S, Thut CJ, McGourty J, Brasher KK, Kinh JA, Gillis S, Mosley B, Ziegler SF and Cosman D: The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255: 1434-1437, 1992.
11. Mosley B, Imus CD, Friend D, Boian N, Thoma B, Park L and Cosman D: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635-32643, 1996.
12. Plun-Favreau H, Perret D, Diveu C, Froger J, Chevalier S, Lelièvre E, Gascan H and Chabbert M: Leukemia inhibitory factor (LIF), cardiotrophin-1, and oncostatin M share structural binding determinants in the immunoglobulin-like domain of LIF receptor. J Biol Chem 278: 27169-27179, 2003.
13. Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-Barthelaix A and Gascan H: Signaling of type II oncostatin M receptor. J Biol Chem 272: 15760-16764, 1997.
14. Thoma B, Bird TA, Friend DJ, Gearing DP and Dower SK: Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 269: 6215-6222, 1994.
15. Dekanty A, Sauane M, Cadenas B, Coluccio F, Barrio M, Casala J, Paciencia M, Rogers F, Coso OA, Piwien-Pilipuk G, Rudland PS and de Asúa LJ: Leukemia inhibitory factor induces DNA synthesis in Swiss mouse 3T3 cells independently of cyclin D1 expression through a mechanism involving MEK/ERK1/2 activation. J Biol Chem 281: 6136-6143, 2006.
16. Liu J, Spence MJ, Wallace PM, Forcier K, Hellstrom I and Vestal RE: Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth, antagonism of growth factors, and down regulation of c-myc protooncogene. Cell Growth Differ 8: 667-676, 1997.
17. Liu J, Hadjokas N, Mosley B, Estro Z, Spence MJ and Vestal RE: Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine 10: 295-302, 1998.
18. Song HY, Kim MR, Lee MJ, Jeon ES, Bae YC, Jung JS and Kim JH: Oncostatin M decreases adiponectin expression and induces dedifferentiation of adipocytes by JAK3- and MEK-dependent pathways. Int J Biochem Cell Biol 39: 439-449, 2007.
19. Miyaoka Y, Tanaka M, Naiki T and Miyajima A: Oncostatin M inhibits adipogenesis through the RAS/ERK and STAT5 signaling pathways. J Biol Chem 281: 37913-37920, 2006.
20. Dierssen U, Beraza N, Lutz HH, Liedtke C, Ernst M, Wasmuth HE and Trautwein C: Molecular dissection of gp130-dependent pathways in hepatocytes during liver regeneration. J Biol Chem 283: 9886-9895, 2008.
21. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F and Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt2): 297-314, 1998.
22. Zhang F, Li C, Halfter H and Liu J: Delineating an oncostatin M-activated STAT3 signaling pathway that modulates gene expression and cellular responses in MCF-7 cells. Oncogene 22: 894-905, 2003.
23. Li C, Kraemer FB, Ahlborn TE and Liu J: Induction of LDL receptor transcription by oncostatin M is mediated by the ERK signaling pathway and the repeat 3 element of the LDL receptor promoter. J Biol Chem 274: 6747-6753, 1999.
24. Kino T, Rice KC and Chrousos GP: The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur J Clin Invest 37: 425-433, 2007.
25. Hekerman P, Zeidler J, Korfmacher S, Bamberg-Lemper S, Knobelspies H, Zabeau L, Tavernier J and Becker W: Leptin induces inflammation-related genes in RINm5F insulinoma cells. BMC Mol Biol 8: 41-45, 2007.
26. Albrecht U, Yang X, Asselta R, Keitel V, Tenchini ML, Ludwig S, Heinrich PC, Häussinger D, Schaper F and Bode JG: Activation of NF-kappaB by IL-1beta blocks IL-6-induced sustained STAT3 activation and STAT3-dependent gene expression of the human gamma-fibrinogen gene. Cell Signal 19: 1866-1878, 2007.
27. Herbert JM, Bernat A and Chatenet-Duchene L: Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats. Blood Coagul Fibrinolysis 10: 239-244, 1999.
28. Boulanger MJ, Bankovich AJ, Kortemme T, Baker D and Garcia KC: Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell 12: 577-589, 2003.
29. Huyton T, Zhang JG, Luo CS, Lou MZ, Hilton DJ, Nicola NA and Garrett TP: An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor. Proc Natl Acad Sci USA 104: 12737-12742, 2007.
30. Deller MC, Hudson KR, Ikemizu S, Bravo J, Jones EY and Health JK: Crystal structure and functional dissection of the cytostatic cytokine oncostatin M. Structure 8: 863-874, 2000.
31. Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, Ochs V, Marquardt H, Zarling JM, Shoyab M, Wei CM, Linsley PS and Rose TM: Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol 9: 2847-2853, 1989.
32. Russell RB and Barton GJ: Multiple protein sequence alignment from tertiary structure comparison: assignment of global and residue confidence levels. Proteins 14: 309-323, 1992.
33. Sali A and Blundell TL: Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 234: 779-815, 1993.
34. Dominguez C, Boelens R, Bonvin AM: HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125: 1731-1737, 2003.
35. Guex N and Peitsch MC: SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723, 1997.
36. Cozzetto D and Tramontano A: Relationship between multiple sequence alignments and quality of protein comparative models. Proteins 58: 151-157, 2005.